12 Jul 2013, BioSpectrum Bureau , BioSpectrum
Singapore: EnVivo Pharmaceuticals, US based drug developer of central nervous system has appointed Dr. Deborah Dunsire, as president and chief executive officer.
Dr. Dunsire served as president and chief executive officer of Millennium Pharmaceuticals, now Millennium: The Takeda Oncology Company, from 2005 to 2013. The company was acquired by Takeda Pharmaceutical in 2008 for $8.8 billion and became Millennium: The Takeda Oncology Company. Dr. Dunsire was the first woman appointed to Takeda's board of directors.
"Deborah's ability to build a fully integrated biopharmaceutical company with an award-winning culture of innovation and successfully commercialize late-stage programs while developing a leading research pipeline is unparalleled," said Dr. Stephen Knight, Chairman of the EnVivo board of directors and president of Fidelity Biosciences.
"She joins EnVivo at a transformative point in the company's evolution, as our lead product, EVP-6124, is in Phase 3 clinical trials in schizophrenia and will enter a Phase 3 clinical trial in Alzheimer's disease later this year. We are excited to work with Deborah to build EnVivo toward global CNS leadership.